ArticleUpsala journal of medical sciences2026
De novo development of JAK2V617F-positive polycythemia vera following allogeneic hematopoietic stem cell transplantation: a report of two rare cases.
Article in Upsala journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Post-transplant erythrocytosis following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rare and has been reported mainly in patients with aplastic anemia and, less frequently, after transplantation for other hematologic conditions. Here, we present two cases of JAK2V617F-positive polycythemia vera (PV) developing after allo-HSCT performed for chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). Case presentations: Discussion: Possible explanations for the development of a JAK2V617F mutation after allo-HSCT include the expansion of a pre-existing but clinically silent mutant clone in the donor, or the emergence of de novo mutations in donor or recipient cells as a result of proliferative stress, immunosuppression, or prior chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.